Blood Tests Studying Hormone Treatment and Alzheimer Disease After Menopause
Studies blood samples from postmenopausal women to learn about hormone treatment and Alzheimer disease.
Plain-language title generated from the registry record
Registry title: Hormone Replacement Trial Against ALzheimers' Disease
Key facts
- Where
- Ghent, BelgiumSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 65 years old?
Source: NCT04312399, who can take part
Where in Belgium
- Ghent university hospitalGhent, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Ghent
- Trial code
- NCT04312399
- Record updated
- 27 January 2025
- Original description
The influence of postmenopausal hormone treatment on dementia is not clear. Dysfunctions in the metabolism of amyloid in the disease of Alzheimer result in an elevated presence of degradation products in cerebrospinal fluid.Read full original descriptionShow less
Hormone Replacement Trial Against ALzheimers' Disease
The influence of postmenopausal hormone treatment on dementia is not clear. Dysfunctions in the metabolism of amyloid in the disease of Alzheimer result in an elevated presence of degradation products in cerebrospinal fluid.
The degradation products in blood will be analysed during the trial, to get better insight in menopause and the start of hormonal therapy.
Postmenopausal women with and without history of breast cancer will be recruited for the trial.
Inclusion: postmenopausal women; 40 - 65 years.
Exclusion: Alcohol and/or drug abuse; hypertension; medical history of psychiatric comorbidity; medical history of neurologic symptoms with cognitive symptoms; Longer than 10 years in menopause; thyroid dysfunction.